Abeona Therapeutics 배당금 및 환매

배당금 기준 확인 0/6

Abeona Therapeutics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-33.6%

환매 수익률

총 주주 수익률	-33.6%
미래 배당 수익률	n/a
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Aug 16

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Mar 31

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Oct 19

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Oct 04

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Aug 11

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Jul 20

Abeona crashes 21% as reverse stock split takes effect

Jul 05

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Mar 02

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Aug 17

Abeona Therapeutics shares rise after letter to stockholders

May 26

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Apr 28

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Feb 21

How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 19

What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Dec 15

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 ABEO 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: ABEO 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Abeona Therapeutics 시장 대비 배당 수익률

ABEO 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (ABEO)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.2%
업계 평균 (Biotechs)	2.3%
애널리스트 예측 (ABEO) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ABEO 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ABEO 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ABEO 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: ABEO 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Abeona Therapeutics 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Consensus EPS estimates fall by 14%

Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

Consensus revenue estimates decrease by 33%, EPS upgraded

Abeona Therapeutics Inc. Announces Board Appointments

Independent Director notifies of intention to sell stock

Independent Director recently bought US$52k worth of stock

New major risk - Negative shareholders equity

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$1.36 loss

Abeona Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $75.000174 million.

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Price target decreased by 7.1% to US$19.50

Consensus revenue estimates fall by 10%

New major risk - Financial position

Abeona Therapeutics Inc. Provides Regulatory Update on Pz-Cel

Abeona Therapeutics Inc., Annual General Meeting, Apr 24, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

President recently bought US$88k worth of stock

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Forecast to breakeven in 2026

Abeona Therapeutics Inc. Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

Abeona Therapeutics Inc. Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

Forecast to breakeven in 2025

New minor risk - Share price stability

New minor risk - Insider selling

Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics Inc. Appoints Madhav Vasanthavada as Chief Commercial Officer

Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$2.08 loss in 2Q 2022)

Abeona Therapeutics Announces Additional Phase 3 Viital Study Results for Eb-101 Presented At the International Societies for Investigative Dermatology 2023 Meeting

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Price target increased to US$29.00

High number of new and inexperienced directors

Abeona Therapeutics Inc. announced that it expects to receive $35.000004 million in funding from Adage Capital Management, L.P., Armistice Capital LLC, EcoR1 Capital, LLC, Nantahala Capital Management, LLC, Deerfield Management Company, L.P. Series C and other investors

Consensus forecasts updated

Abeona Therapeutics Inc. announced that it expects to receive $35.000004 million in funding from Adage Capital Management, L.P., Armistice Capital LLC, EcoR1 Capital, LLC, Nantahala Capital Management, LLC, Deerfield Management Company, L.P. Series C

Abeona Therapeutics Inc. Announces Database Lock for Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Abeona Therapeutics Inc. Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Consensus forecasts updated

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Abeona Therapeutics Inc., Annual General Meeting, Aug 17, 2022

Consensus forecasts updated

Abeona crashes 21% as reverse stock split takes effect

Consensus revenue estimates increase by 95%

Nasdaq Grants Second 180-Day Period to Abeona Therapeutics to Regain Compliance with Minimum Bid Price Rule

Price target decreased to US$2.00

High number of new and inexperienced directors

Consensus forecasts updated

Abeona Therapeutics Inc. Reports Goodwill Impairment Charge for the Fourth Quarter Ended December 31, 2021

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Price target decreased to US$4.50

High number of new directors

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Abeona Therapeutics Inc. Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 Viital Study for Recessive Dystrophic Epidermolysis Bullosa

Price target decreased to US$4.67

Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 3000E Value Index

Abeona Therapeutics shares rise after letter to stockholders

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

President notifies of intention to sell stock

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Independent Director recently sold US$310k worth of stock

Independent Director exercised options and sold US$342k worth of stock

Abeona Therapeutics Inc. Announces New Positive Data from Two Ongoing Phase 1/2 Clinical Trials of its Investigational AAV-Based Gene Therapies ABO-102 and ABO-101 in MPS IIIA and MPS IIIB

New 90-day high: US$2.34

Abeona Therapeutics Inc. Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa

How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

New 90-day high: US$1.84

What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?